Cycas Hospitality Opens First Property Outside UK and Boosts Senior Development Team as Part of European Rollout
Cycas Hospitality, one of the largest branded extended-stay hotels operators in the UK, has demonstrated its commitment to European expansion by opening its first property in continental Europe and growing its acquisition and development team through three new appointments.
Cycas Hospitality has opened a dual-branded property under Marriott’s Moxy and Residence Inn brands. The hotels are located on Amsterdam’s western harbour front in the Houthavens area - the city’s emerging creative and fashion district. The hotels have been realised in collaboration with the developer Heren2, and will be managed by Cycas Hospitality under a franchise from Marriott International.
The opening of these hotels is the first step of Cycas’s ambitious plan to continue the rollout of extended-stay hotels throughout Europe. With a key focus on the United Kingdom, the Benelux countries, France and Germany, the extended-stay specialist’s ambition is to treble its number of guest rooms from 3,000 open and operating, or signed and in the pipeline, to more than 10,000 in the next five years.
In order to facilitate this growth, Cycas has expanded its development and acquisition team, which is led by Ms. Asli Kutlucan. The new team members are:
- Lisa Neubueser, who formerly worked for Dutch extended-stay brand Zoku International and was previously Director of Hotel Fund Management at Invesco Real Estate in London, where she oversaw a European hotel real estate portfolio of more than €1 billion. Lisa takes the role of Director of Development and Acquisition, expanding Cycas’s presence in Europe, starting with Germany.
- Nicole Perreten, who formerly worked with international hospitality consulting firm HVS and will lead the Cycas feasibility team as Head of Feasibility.
- Christos Georgiou, whose experience includes roles with Spitfire Capital Advisors, UBS and Nomura. Christos will be Business Development Manager, focusing on expansion in the UK and M&A transactions.
The expansion of the development and acquisition team follows a multi-million-Euro investment from Hua Kee in Cycas. The Thai family office and sizeable hotel owner and operator in Southeast Asia, Australia and Europe acquired a one-third share in Cycas, and its investment provides the business not only with additional working capital but also a co-investment partner and potential for future deals.
Cycas Hospitality’s turnover under management is forecast to treble over the next two years from €38 million to over €100 million, based purely on the business’s existing, secured and signed pipeline of hotels.
Eduard Elias, Partner & Co-founder at Cycas Hospitality, said:
“These new hotels, coupled with the expansion of our development and acquisition team, cement our position as the European leader in extended-stay accommodation and prepare us for further growth. With the capital in place to fund our ambitions and a bolstered team now on board to make them a reality, we are actively looking for new sites to operate across continental Europe, capitalising on increasing demand from travellers who value independence and flexibility.
“As well as launching our first hotels in continental Europe, this is the first time we have operated Marriott’s vibrant Moxy brand and we look forward to providing a warm welcome to guests in this exciting part of Amsterdam.”
Asli Kutlucan, Partner at Cycas Hospitality, said:
“Whereas extended stay is already established in the US, there is an enormous opportunity to expand this emerging asset class in Europe. I’m confident we’ve hired the best people in the business to ensure Cycas remains at the forefront of this rapidly evolving market and accelerate our international growth.”
The new hotels in Amsterdam Houthavens are Marriott’s second dual-branded property in Europe. The Moxy Amsterdam Houthavens offers 120 bedrooms, seven meeting rooms, a bar and lounge with an energetic, contemporary vibe. The Residence Inn Amsterdam Houthavens, meanwhile, features 60 studios and one-bedroom suites. The hotels share a pool, sauna and gym.
Notes to Editors
About Cycas Hospitality
- Founded in 2007, Cycas Hospitality is a specialist in extended-stay hotels, managing over 1,450 suites and rooms across 11 properties. These are located in key city centre locations across the UK (London, Liverpool, Newcastle) and include Cycas’s first property in mainland Europe (Amsterdam).
- Cycas Hospitality partners with institutional and private investors to maximise the full potential of their hotel assets. Its current clients include Starwood Capital, M&L Hospitality, and CLS Holdings plc.
- Extended-stay hotels are notable for their efficient operating model and high margins; historically, long-stay hotels have outperformed the standard hotel model during times of recession and recovered faster to pre-crisis levels and strong growth is forecast for the sector in Europe
- Following recent investment from the family-owned Hua Kee Group, Cycas will open three further properties by summer 2018 and intends to grow its portfolio to more than 10,000 guest rooms in the next five years.
- Having pioneered the branded extended-stay hotel concept in Europe, Cycas is London’s leading operator in this field and a partner of choice for major global hotel franchise brands plus international investors. In Europe, Cycas is the largest extended-stay operator for IHG’s Staybridge Suites brand and Marriott’s Residence Inn, and helped develop the dual-branded hotel concept for each company.
- The heart of Cycas’s first-class guest experience is a dedicated Culture Team who ensure each property operates with Cycas’s signature "positively outrageous service" and the philosophy that "our job is not over until we get a smile."
- Cycas delivers a combination of expertise in hotel operations, property development and asset management. Its overarching goal is to become one of the best hospitality employers on the market, making its hotels the best places to work as well as stay.
- To find out more visit www.cycashospitality.com or connect with us via LinkedIn, Twitter and Facebook.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 13:45 | Tiedote
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 12:10 | Tiedote
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting21.10.2018 01:30 | Tiedote
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 20:37 | Tiedote
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10 | Tiedote
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00 | Tiedote
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme